MAP2K1 and non-small cell lung carcinoma: Focusing on the MAPK pathway in a larger phase III randomized study (N = 510), selumetinib (a MEK1 and MEK2 inhibitor) did not show an improvement in combination with docetaxel for the PFS (primary endpoint: 3.9 vs. 2.8 months, p = 0.44) or OS in pre-treated metastatic NSCLC patients [58].